Comparative safety signal prioritization of CDK4/6 inhibitors in breast cancer: a FAERS pharmacovigilance, machine learning, and clinical contextualization study.
Journal: Frontiers in pharmacology
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Fan L, Liu S, Tang Y, et al. (2026). "Comparative safety signal prioritization of CDK4/6 inhibitors in breast cancer: a FAERS pharmacovigilance, machine learning, and clinical contextualization study.". Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1889178